Ebola outbreak news in Congo drives speculative premarket surge in VRAX

• Reuters reported May 19 that WHO awaits six tons of supplies as Ebola outbreak grows in DRC (following mid-May PHEIC declaration).
• Traders on X and forums linked news to Virax’s commercial ImmuneSelect Ebola Zaire peptide pool for T-cell immunology and vaccine research.
• Stock gained ~45.83% in pre-market May 19, extending 53% rally on May 18 (close $0.235) with extreme volume (~760M shares).
• High short interest (previously >70% of float), low float, and penny-stock momentum triggered violent short squeeze.
• Builds on May 15 Armistice Capital 13G filing (~4.99% stake) and May 2026 RedChip investor awareness/TV campaign.
• Virax primarily develops ViraxImmune T-cell diagnostics for PAIS/Long COVID; Ebola product provided timely thematic catalyst.
• No new company PR or earnings; movement is retail-driven speculation per social media and Benzinga coverage.

https://finviz.com/quote?t=VRAX&p=d